• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Philip Adamson, M.D., M.Sc.: The Relationship Between Cardiovascular Manifestations and COVID-19


Philip Adamson, M.D., M.Sc., details the relationship between cardiovascular manifestations and COVID-19.

Cardiovascular manifestations of COVID-19 can be devastating and lead to the need for advanced therapies that are required in intensive care units. Managed Healthcare Executive® had the chance to speak with Philip B. Adamson, M.D., M.Sc., FACC, divisional vice president of Global Clinical Affairs, and chief medical officer of Abbott Laboratories, about the relationship between COVID-19 and heart disease.

Angiotensin receptors are located in every tissue in the body, including the heart and they allow viruses to enter all the cells in the body — even the heart cells. The systemic inflammation damages all the organs, including the heart, and can be quite profound considering the damage done and can give rise to cardiovascular complications. And these events can be thrombotic and direct heart tissue directly.

“I think that the microvascular thrombosis that occurs, even when this profound procoagulant state is not clinically present, seems to not only impact the lungs with micro thrombotic complications, but also the heart,” Adamson said.

Still, it’s difficult to tell what’s going to happen in several years to those who have survived the moderate to severe cases, he said.

“In two years, will we see a pandemic have dilated cardiomyopathies as a result of this process that has sensitized them, the heart to a chronic slow burn, immune damage — that could be a long-term sequela of this — we don’t know. And so, I certainly hope that early intervention will prevent the sequela,” Adamson added.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.